Kala Bio enters exclusive US distribution deal with Virotek for ophthalmology genetic testing program

• Kala Bio entered an exclusive U.S. distribution and reseller agreement with Virotek on Sept. 3, 2026 for an ophthalmology genetic testing program.
• Exclusivity hinges on a Sept. 3, 2027 milestone; failure triggers a 30-day cure period, then converts the deal to non-exclusive.
• Kala will lead commercialization; Virotek will deliver and administer the program.
• Net profit will be split 50-50 once Virotek recoups cost of goods sold; terms to be reviewed monthly.
• Five-year initial term starting Sept. 3, 2026; Kala receives a right of first refusal on Virotek dispositions of ophthalmological products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-009999), on September 10, 2026, and is solely responsible for the information contained therein.